98 related articles for article (PubMed ID: 23670898)
1. Comparison of contrast agents for atherosclerosis imaging using cultured macrophages: FDG versus ultrasmall superparamagnetic iron oxide.
Satomi T; Ogawa M; Mori I; Ishino S; Kubo K; Magata Y; Nishimoto T
J Nucl Med; 2013 Jun; 54(6):999-1004. PubMed ID: 23670898
[TBL] [Abstract][Full Text] [Related]
2. Vascular and plaque imaging with ultrasmall superparamagnetic particles of iron oxide.
Alam SR; Stirrat C; Richards J; Mirsadraee S; Semple SI; Tse G; Henriksen P; Newby DE
J Cardiovasc Magn Reson; 2015 Sep; 17(1):83. PubMed ID: 26381872
[TBL] [Abstract][Full Text] [Related]
3. A Novel Bivalent Mannosylated Targeting Ligand Displayed on Nanoparticles Selectively Targets Anti-Inflammatory M2 Macrophages.
Chen P; Zhang X; Venosa A; Lee IH; Myers D; Holloway JA; Prud'homme RK; Gao D; Szekely Z; Laskin JD; Laskin DL; Sinko PJ
Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32182675
[TBL] [Abstract][Full Text] [Related]
4. Fast field-cycling magnetic resonance detection of intracellular ultra-small iron oxide particles in vitro: Proof-of-concept.
Abbas H; Broche LM; Ezdoglian A; Li D; Yuecel R; James Ross P; Cheyne L; Wilson HM; Lurie DJ; Dawson DK
J Magn Reson; 2020 Apr; 313():106722. PubMed ID: 32248086
[TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance Imaging Nanoprobe Quantifies Nitric Oxide for Evaluating M1/M2 Macrophage Polarization and Prognosis of Cancer Treatments.
Liu X; Wang M; Jiang Y; Zhang X; Shi C; Zeng F; Qin Y; Ye J; Hu J; Zhou Z
ACS Nano; 2023 Dec; 17(24):24854-24866. PubMed ID: 38047965
[TBL] [Abstract][Full Text] [Related]
6. The innovative checkpoint inhibitors of lung adenocarcinoma, cg09897064 methylation and ZBP1 expression reduction, have implications for macrophage polarization and tumor growth in lung cancer.
Wang A; Zheng WS; Luo Z; Bai L; Zhang S
J Transl Med; 2024 Feb; 22(1):173. PubMed ID: 38369516
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Applications of Ultrasmall Superparamagnetic Particles of Iron Oxide for Imaging Myocardial and Vascular Inflammation.
Merinopoulos I; Gunawardena T; Stirrat C; Cameron D; Eccleshall SC; Dweck MR; Newby DE; Vassiliou VS
JACC Cardiovasc Imaging; 2021 Jun; 14(6):1249-1264. PubMed ID: 32861658
[TBL] [Abstract][Full Text] [Related]
8. Inhaled silica nanoparticles exacerbate atherosclerosis through skewing macrophage polarization towards M1 phenotype.
Stachyra K; Wiśniewska A; Kiepura A; Kuś K; Rolski F; Czepiel K; Chmura Ł; Majka G; Surmiak M; Polaczek J; van Eldik R; Suski M; Olszanecki R
Ecotoxicol Environ Saf; 2022 Jan; 230():113112. PubMed ID: 34953274
[TBL] [Abstract][Full Text] [Related]
9. Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation.
Gustafsson B; Youens S; Louie AY
Bioconjug Chem; 2006; 17(2):538-47. PubMed ID: 16536488
[TBL] [Abstract][Full Text] [Related]
10. TIPS pentacene loaded PEO-PDLLA core-shell nanoparticles have similar cellular uptake dynamics in M1 and M2 macrophages and in corresponding in vivo microenvironments.
McDaniel DK; Jo A; Ringel-Scaia VM; Coutermarsh-Ott S; Rothschild DE; Powell MD; Zhang R; Long TE; Oestreich KJ; Riffle JS; Davis RM; Allen IC
Nanomedicine; 2017 Apr; 13(3):1255-1266. PubMed ID: 28040495
[TBL] [Abstract][Full Text] [Related]
11. Imaging Macrophage-associated Inflammation.
Foss CA; Sanchez-Bautista J; Jain SK
Semin Nucl Med; 2018 May; 48(3):242-245. PubMed ID: 29626941
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory zymosan/ι-carrageenan/ agarose hydrogel for targeting M2 to M1 macrophages (antitumoral).
Venkatachalam G; Giri J; Mallik S; Arumugam GS; Arulmani M; Dewangan VK; Doble M; Zhao Z
RSC Adv; 2024 Apr; 14(17):11694-11705. PubMed ID: 38605900
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced Granulomatous Panniculitis: Polarization of M1/M2 Macrophages.
Tani N; Yamada N; Yoshida Y
Acta Derm Venereol; 2023 Dec; 103():adv18855. PubMed ID: 38124380
[No Abstract] [Full Text] [Related]
14. Author Correction: A second-generation M1-polarized CAR macrophage with antitumor efficacy.
Lei A; Yu H; Lu S; Lu H; Ding X; Tan T; Zhang H; Zhu M; Tian L; Wang X; Su S; Xue D; Zhang S; Zhao W; Chen Y; Xie W; Zhang L; Zhu Y; Zhao J; Jiang W; Church G; Chan FK; Gao Z; Zhang J
Nat Immunol; 2024 Mar; 25(3):576. PubMed ID: 38110523
[No Abstract] [Full Text] [Related]
15. Bioenergetic profiles diverge during macrophage polarization: implications for the interpretation of 18F-FDG PET imaging of atherosclerosis.
Tavakoli S; Zamora D; Ullevig S; Asmis R
J Nucl Med; 2013 Sep; 54(9):1661-7. PubMed ID: 23886729
[TBL] [Abstract][Full Text] [Related]
16. Macrophages at the fork in the road to health or disease.
Mills CD; Lenz LL; Ley K
Front Immunol; 2015; 6():59. PubMed ID: 25762997
[No Abstract] [Full Text] [Related]
17. Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches.
Soni SS; D'Elia AM; Rodell CB
Drug Deliv Transl Res; 2023 Jul; 13(7):1983-2014. PubMed ID: 36763330
[TBL] [Abstract][Full Text] [Related]
18. Unravelling the role of macrophages in cardiovascular inflammation through imaging: a state-of-the-art review.
Parry R; Majeed K; Pixley F; Hillis GS; Francis RJ; Schultz CJ
Eur Heart J Cardiovasc Imaging; 2022 Nov; 23(12):e504-e525. PubMed ID: 35993316
[TBL] [Abstract][Full Text] [Related]
19. Re-engineered imaging agent using biomimetic approaches.
Nguyen TDT; Marasini R; Aryal S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jan; 14(1):e1762. PubMed ID: 34698438
[TBL] [Abstract][Full Text] [Related]
20. Coronary plaque instability assessed by positron emission tomography and optical coherence tomography.
Galiuto L; Leccisotti L; Locorotondo G; Porto I; Burzotta F; Trani C; Niccoli G; Leone AM; Danza ML; Melita V; Fedele E; Stefanelli A; Giordano A; Crea F
Ann Nucl Med; 2021 Oct; 35(10):1136-1146. PubMed ID: 34273103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
